129779-30-2

Basic information

• Product Name: 1-BOC-3,5-DIMETHYL-PIPERAZINE
• Synonyms: (3R,5S)-3,5-DIMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-3,5-DIMETHYL-PIPERAZINE;1-BOC-CIS-3,5-DIMETHYL-PIPERAZINE;CIS-3,5-DIMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;5-DiMethyl-piperazine-1-carboxylic acid tert-butyl ester;cis-3;1-Piperazinecarboxylic acid, 3,5-diMethyl-, 1,1-diMethylethyl ester, (3R,5S)-;(3R,5S)-rel-tert-Butyl 3,5-diMethylpiperazine-1-carboxylate
• CAS NO: 129779-30-2
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Mol File: 129779-30-2.mol

Chemical Properties

• Boiling Point: 279.7±15.0℃ (760 Torr)
• Flash Point: 123.0±20.4℃
• Appearance: /
• Density: 0.970±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.452
• Storage Temp.: -20°C
• PKA: 8.58±0.60(Predicted)
• CAS DataBase Reference: 1-BOC-3,5-DIMETHYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3,5-DIMETHYL-PIPERAZINE(129779-30-2)
• EPA Substance Registry System: 1-BOC-3,5-DIMETHYL-PIPERAZINE(129779-30-2)

Safety Data

• Hazard Codes: N
• Statements: 36/37/38-50
• Safety Statements: 26-61
• RIDADR: UN3077
• Hazardous Substances Data: 129779-30-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-3,5-DIMETHYL-PIPERAZINE is used as a pharmaceutical intermediate for the development of various drugs, particularly in the synthesis of 7-(3-(Piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives. These derivatives have been identified as highly potent, selective, and orally bioavailable PI3Kδ inhibitors, which play a significant role in the treatment of various diseases, including cancer and autoimmune disorders.
In the field of medicinal chemistry, 1-BOC-3,5-DIMETHYL-PIPERAZINE's unique structure allows for the creation of novel compounds with potential therapeutic applications, making it a valuable asset in drug discovery and development processes.

InChI:InChI=1/C11H22N2O2/c1-8-6-13(7-9(2)12-8)10(14)15-11(3,4)5/h8-9,12H,6-7H2,1-5H3/t8-,9+

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 21655-48-1 cis-2,6-dimethylpiperazine 
• 108-49-6 3,5-dimethylpiperazine 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 129785-64-4 (pentachlorophenyl)-4--2,6-dimethylpiperazin-1-yl>-1,2,5-thiadiazol-3-carboxylate 
• 1124214-79-4 (3S,5R)-tert-butyl 4-(3-(tert-butylcarbamoyl)benzyl)-3,5-dimethylpiperazine-1-carboxylate 
• 1258305-26-8 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one 
• 1258305-28-0 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one citrate 
• 1124214-75-0 N-tert-Butyl-3-(((2S,6R)-4-(4-(3-cyclobutylureido)benzoyl)-2,6-dimethylpiperazin-1-yl)methyl)benzamide 2,2,2-trifluoroacetate 

Relevant articles and documents

TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Amino pyrimidine compound and preparation method and application thereof

The invention relates to an amino pyrimidine compound and a preparation method and application thereof. The amino pyrimidine compound has a structure as shown in a formula I. The formula is shown in the description. The compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The invention further relates to a medicine composition comprising the compound, a preparation methodand application thereof in preparation of anti-tumor medicines.

BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION

The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto- temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

Quinazolinone PARP-1 inhibitors, medicinal composition containing inhibitors, and antitumor use of inhibitors

The invention discloses quinazolinyl-2,4(1H,3H)-dione PARP-1 inhibitors, and a preparation method, a medicinal composition and a use thereof. The invention concretely relates to quinazolinyl-2,4(1H,3H)-dione derivatives represented by general formula I, a medicinal salt and a preparation method thereof, a composition containing one or more of the compounds, and a use of the compounds in the preparation of tumor prevention and/or treatment medicines.

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer

After a high-throughput screening campaign identified thioether 1 as an antagonist of the nuclear androgen receptor, a zone model was developed for structure-activity relationship (SAR) purposes and analogues were synthesized and evaluated in a cell-based luciferase assay. A novel thioether isostere, cyclopropane (1S,2R)-27, showed the desired increased potency and structural properties (stereospecific SAR response, absence of a readily oxidized sulfur atom, low molecular weight, reduced number of flexible bonds and polar surface area, and drug-likeness score) in the prostate-specific antigen luciferase assay in C4-2-PSA-rl cells to qualify as a new lead structure for prostate cancer drug development.

5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS

The present invention discloses compounds according to Formula (I), wherein R, R2, R3a, R3b, and Cy are as defined herein. The present invention discloses compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same and methods for the prophylaxis and/or treatment of inflammatory conditions and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis.

NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

COMPOUND FOR INHIBITING TYPE 5 PHOSPHODIESTERASE AND PREPARATION METHOD THEREOF

The present invention discloses a compound of formula (I) and citrate thereof as type 5 phosphodiesterase inhibitor, a preparation method thereof, and a pharmaceutical composition including the compound of formula (I) and citrate thereof. The experimental results of the present invention prove that the compound of formula (I) and citrate thereof can inhibit activity of type 5 phosphodiesterase, and can be used for treating erectile dysfunction, inhibiting platelet aggregation and treating thrombosis, decreasing pulmonary hypertension and treating cardiovascular diseases, treating asthma and treating diabetes gastroparesis.

COMPOUND FOR INHIBITING TYPE 5 PHOSPHODIESTERASE AND PREPARATION METHOD THEREOF

The present invention discloses a compound of formula (I) and citrate thereof as type 5 phosphodiesterase inhibitor, a preparation method thereof, and a pharmaceutical composition including the compound of formula (I) and citrate thereof. The experimental results of the present invention prove that the compound of formula (I) and citrate thereof can inhibit activity of type 5 phosphodiesterase, and can be used for treating erectile dysfunction, inhibiting platelet aggregation and treating thrombosis, decreasing pulmonary hypertension and treating cardiovascular diseases, treating asthma and treating diabetes gastroparesis.

N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES

The present invention relates to N-benzyl,N′-arylcarbonylpiperazine derivatives having the general formula I to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N′-arylcarbonylpiperazine derivatives for the manufacture o